Report Overview

The EU Brain cancer drugs market size stood at USD XX billion in 2019 and is projected to reach USD XX billion by 2028, exhibiting a CAGR of XX% during the forecast period

Brain cancer is a disease in which the cancer cells grow to form a mass cancer tissue that intervenes with other brain functions such as muscle control, sensation, memory & other body functions. Cancer cells developing from brain tissue are termed primary brain tumors while tumors that proliferate from other body parts to the brain are termed metastatic tumors. EU is expected to contribute significantly to this space over the forecast period, which can be attributed to the increasing prevalence of malignant cancers in countries like the U.K. In the EU, the standardized incidence of primary brain cancers ranges from 4.5 to 11.2 cases per 100,000 men and from 1.6 to 8.5 per 100,000 women. The two most common brain cancers, high-grade glioma and brain metastasis occur more frequently during adulthood and especially among the elderly



 

Market Growth Drivers

The market size drivers for the growth of the brain cancer drug market in the EU are expected to propel by technological developments. Additionally, significance in the rise of brain cancer is expected to grow in the upcoming years. The rise in the number of cigarette smokers responsible for brain cancer has contributed to the market size. However, major restraints comprise heavy costs associated with diagnosis, low awareness levels, and lesser accessibility